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Abstract 
Background: Cystic fibrosis (CF) is a life‑threatening multiorgan genetic disease, particularly affecting the lungs, 
where recurrent infections are the main cause of reduced life expectancy. In CF, mutations in the gene encoding 
the cystic fibrosis transmembrane conductance regulator (CFTR) protein impair transepithelial electrolyte and water 
transport, resulting in airway dehydration, and a thickening of the mucus associated with abnormal viscoelastic 
properties. Our aim was to develop a rheological method to assess the effects of hypertonic saline (NaCl) and  NaHCO3 
on CF sputum viscoelasticity in vitro, and to identify the critical steps in sample preparation and in the rheological 
measurements.
Methods: Sputum samples were mixed with hypertonic salt solutions in vitro in a ratio of either 10:4 or 10:1. Distilled 
water was applied as a reference treatment. The rheological properties of sputum from CF patients, and the effects 
of these in vitro treatments, were studied with a rheometer at constant frequency and strain, followed by frequency 
sweep tests, where storage modulus (G′), loss modulus (G″) and loss factor were determined.
Results: We identified three distinct categories of sputum: (i) highly elastic (G′ > 100,000 Pa), (ii) elastic 
(100,000 Pa > G′ > 1000 Pa), and (iii) viscoelastic (G′ < 1000). At the higher additive ratio (10:4), all of the added solutions 
were found to significantly reduce the gel strength of the sputum, but the most pronounced changes were observed 
with  NaHCO3 (p < 0.001). Samples with high elasticity exhibited the greatest changes while, for less elastic samples, a 
weakening of the gel structure was observed when they were treated with water or  NaHCO3, but not with NaCl. For 
the viscoelastic samples, the additives did not cause significant changes in the parameters. When the lower additive 
ratio (10:1) was used, the mean values of the rheological parameters usually decreased, but the changes were not 
statistically significant.
Conclusion: Based on the rheological properties of the initial sputum samples, we can predict with some confidence 
the treatment efficacy of each of the alternative additives. The marked differences between the three categories sug‑
gest that it is advisable to evaluate each sample individually using a rheological approach such as that described here.
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Introduction
Cystic fibrosis (CF) is one of the most common life-
threatening genetic diseases. It affects many organs, 
including the lungs, where viscous mucus clogs the 
airways and recurrent infections shorten the patients’ 
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lifespan [1]. In CF, transepithelial  Cl− and  HCO3− 
transport is impaired due to mutations in the gene 
encoding the cystic fibrosis transmembrane conduct-
ance regulator (CFTR) protein, which functions as a 
cAMP/PKA-regulated epithelial anion channel. Since, 
in addition, CFTR inhibits the activity of the epithelial 
 Na+ channel (ENaC), there is also hyper-reabsorption 
of  Na+ in CF airways. The reduced concentrations of 
 Na+ and  Cl− in the airway surface liquid (ASL) cause 
water depletion, resulting in airway dehydration, and 
a thickening of the mucus associated with abnormal 
viscoelastic properties and osmotic pressures. The 
rheological properties of the mucus strongly influence 
the effectiveness of mucus clearance and cough [2–4]. 
Changes in these properties significantly reduce mucus 
clearance in CF and thus contribute to the coloniza-
tion of the airways by bacteria and the development of 
recurrent infections [5, 6].
Recent studies have focused on impaired transepithe-
lial  HCO3− transport [4, 7, 8] because it has a key role 
in maintaining the normal pH of the ASL. Low levels of 
 HCO3− lead to acidic ASL pH, which favours bacterial 
growth and compromises immune defence. However, 
 HCO3− concentrations also determine the physiologi-
cal properties of mucins. Negatively-charged amino acid 
residues in newly-formed mucin molecules are bound 
to  Ca2+ and protons, which must be removed to ensure 
mucin expansion and hydration during the formation of 
the extracellular mucus gel. Physiologically, this process 
is facilitated by  HCO3−, which can form complexes with 
 Ca2+ and protons [9, 10].
The gel structure of mucus also depends on various 
interactions within and between the mucin molecules. 
Major interactions include disulphide, hydrogen and 
ionic bonds, as well as physical entanglements [11]. In 
dehydrated ASL, the high concentration of mucin mol-
ecules increases the number of crosslinks, resulting in 
highly elastic sputum in CF patients. Mucolytic agents 
are designed to break these crosslinks, thereby improv-
ing the rheological properties of the ASL. Previous stud-
ies have shown that mucus viscosity can be reduced by 
the administration of a hypertonic NaCl solution, which 
disrupts the ionic interactions between the mucin chains 
[11]. In addition, when a hypertonic salt solution (HS) is 
used, fluid moves by osmosis from the interstitial space 
to the airways. This further weakens the gel structure, 
increases the volume of the ASL and stimulates mucocili-
ary clearance (MCC) [12, 13].
The rheological properties of human sputum can be 
a useful indicator of disease severity or progression as 
well as treatment efficacy. In order to assess sputum vis-
coelasticity in clinical practice, a comprehensive under-
standing of practical rheology is required, including 
sample preparation, the choice of parameter settings, 
and knowledge of the external factors influencing the 
measurements.
Our specific aim in this study was to develop a rheo-
logical method for assessing the effects of hypertonic 




Hypertonic solutions, 300  mmol/L sodium chloride 
(Ph.Eur, Hungaropharma Zrt, Budapest, Hungary) and 
300  mmol/L sodium bicarbonate (Ph.Eur, Hungarop-
harma Zrt, Budapest, Hungary), were freshly prepared.
Sputum samples of CF patients (both male and female 
over 18 age) were spontaneously produced and collected 
in the National Korányi Institute for Pulmonology (Buda-
pest, Hungary). Patients were in a stable condition and 
had received neither hypertonic saline nor dornase alfa 
therapy for 8  h before the sputum collection. Sputum 
samples were immediately frozen and stored at − 20  °C. 
Before use, samples were thawed at room temperature. 
All methods were carried out in accordance with relevant 
guidelines and regulations. Experimental protocols were 
approved by both the Ethics Committee of the National 
Korányi Institute for Pulmonology (registration number: 
7/2019) and the Hungarian Medical Research Council 
(ETT-TUKEB, registration number: IV/8155-3/2020/
EKU). Informed consent was obtained from all subjects.
In order to separate the sputum from saliva, samples 
were centrifuged (Hermle centrifuge) at 11,000 RCF for 
10  min [4]. The supernatant saliva was then decanted, 
and the sputum samples from the same patient pooled 
and gently stirred for homogenization with a magnetic 
stirrer at 100 rpm for 10 min. This procedure enabled to 
analyse a concentrated sputum sample.
Sputum samples were divided into aliquots in order to 
compare the effects of different treatments on the same 
samples. Alternative methods (horizontal shaking, ultra-
sonication, magnetic stirring or gentle manual mixing) 
were evaluated for mixing the sputum samples with the 
additives (either water or the hypertonic solutions).
Sputum samples were treated with either distilled 
water (n = 87) or hypertonic NaCl (n = 74) or  NaHCO3 
(n = 55). The ratio of sputum to additive solution was 
either 10:4 or 10:1 by volume.
Rheological methods
The rheological properties of the sputum in CF, and the 
effects of the in  vitro treatments, were studied with a 
Physica MCR302 rheometer (Anton Paar, Austria). The 
measuring device was of parallel plate type (diameter 
25  mm, gap 0.1  mm). The measurements were carried 
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out at 37  °C, and evaporation was blocked with a cap 
containing water.
In the first part of the measurement (the resting phase), 
the structural state of the sputum, and any changes 
resulting from the treatments, were determined over 
30  min at a constant angular frequency of 1  rad/s and 
a constant strain of 0.4%. Each measurement was per-
formed immediately after mixing the solutions and gentle 
agitation.
Viscoelastic characteristics were determined by fre-
quency-sweep tests immediately after the resting-phase 
measurement, using a strain of 0.4%. Storage modu-
lus (G′), loss modulus (G″) and loss factor (tanδ) were 
determined over an angular frequency range from 0.1 to 
100  rad/s. The strain value (0.4%) used in the measure-
ments was within the linear range of the viscoelasticity of 
the sputum.
We assessed both untreated and treated samples for 
each sputum specimen. During the development of the 
methodology, parallel samples from the same patient col-
lected at a given time were used for the comparison of 
the different treatments.
Statistical analysis
One-way ANOVA followed by Dunnett’s test, with 
GraphPad Prism 8.0 software (GraphPad Software Inc., 
San Diego, USA) were applied for statistical analysis. 
p < 0.05 was considered to be statistically significant, 
whereas p ≤ 0.01 and p ≤ 0.001 were considered very and 
highly significant, respectively.
Results
In order to analyse the possible breakdown of mucus 
structure in CF, and to follow the recovery of the spu-
tum samples after their treatment and insertion into the 
rheometer, a constant oscillation test was applied at low 
frequency and strain value. This part of the measure-
ment, here denoted the ‘resting phase’, can be benefi-
cial in gaining insight into the time-dependency of the 
in vitro treatments.
During initial trials of the methodology, we observed 
a strong increase in the G′ value, typical of gelation. The 
samples were routinely protected against evaporation by 
a blocking cap containing water, so these effects could 
have been due either to structural breakdown of the sam-
ple during insertion or to thermogelation of the sputum, 
which had been stored at room temperature before the 
measurements. In order to distinguish between these 
two possibilities, experiments were performed with 
sputum samples pre-incubated at 37  °C for 30  min and 
inserted into the pre-warmed instrument at the same 
temperature. The resting phase of the pre-warmed spu-
tum showed the same characteristics as those that were 
not pre-warmed before the measurements (Fig. 1), indi-
cating that the storage temperature did not influence the 
rheological behaviour of the sputum samples. This result 
suggests a destruction effect of the installation process on 
the gel structure of the sputum.
The effects of different types of agitation were also 
assessed during the development of our in  vitro treat-
ment method. The sputum samples were divided into 3 
parts: (i) untreated, (ii) mixed with an orbital shaker for 
15 min at 450 rpm, and (iii) treated in an ultrasound bath 
for 5 min.
The recovery part of the same sample varied according 
to the different pre-treatments (agitations) (Fig. 2).
The orbital shaker improved the increase in viscoe-
lastic behaviour during the resting phase, while the US 
Fig. 1 Time‑dependent representative changes in the storage 
modulus (G′) of CF sputum samples during the resting phase of 
rheological measurements on pre‑warmed and non‑pre‑warmed 
samples
Fig. 2 Resting phase of representative sputum samples after 
different types of agitation
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destroyed the structure. Sonication resulted in heating 
and the precipitation of some components of the sputum, 
therefore, we discontinued to use this method.
We tried to mimic physiological conditions while per-
forming the in vitro treatments. When hypertonic saline 
solutions are used by inhalation, no real mixing occurs 
because the inhaled saline solution is simply sprayed onto 
the airway surface liquid. Therefore, we applied gentle 
manual agitation at room temperature for 10 s, followed 
by the insertion of the mixture into the rheometer and 
the immediate start of the measurement.
The resting phase was examined for all of the CF spu-
tum samples obtained from the CF patients and sub-
jected either to no treatment or mixing with water, 
hypertonic NaCl or hypertonic NaHCO3. Our data show 
that significant gel structure build-up occurred in some 
samples (Fig. 3).
In many cases the storage modulus G’ of the sputum 
sample increased significantly during the measurements 
(Fig. 3a, d, e, f ), reflecting the recovery of gel structure. 
In some of those cases, the rate of recovery was signifi-
cantly altered by the various pre-treatments. In general, 
the added water or hypertonic solutions slowed down 
recovery (Fig.  3a, c, d), while in some cases they com-
pletely prevented the recovery of the strong gel structure 
(Fig. 3b). In a few cases, however, there were no signifi-
cant changes in this parameter (Fig. 3f ).
This resting phase is very important because the struc-
ture of the sputum can change during insertion into the 
rheometer, and recovery can be observed even in the 
untreated samples, suggesting significant adverse effects 
of the sample insertion procedure.
Mixing with additives and gentle agitation can result in 
slower recovery, and in some cases the gel structure did 
not build up again. In order to gain information about the 
real gel structure and the effect of the pre-treatment and 
the additives, we considered the strong effects of mixing 
and installation on the gel structure and assessed the final 
gel structure, which requires the inclusion of a resting 
phase in the rheological measurements. In most cases, 
the additives delayed the recovery of the gel structure, 
but no significant differences were revealed between the 
effects of the additives.
The effects of the different additives were evaluated in 
detail based on frequency-sweep tests. Storage and loss 
moduli, G′ and G″ respectively, of both untreated and 
treated sputum samples were compared with each other. 
The values were interpreted at angular frequencies of 1 
and 10 rad/s.
A centrifugation was applied during the sputum sam-
ples preparation, which resulted in a concentrated spu-
tum sample [4]. Despite of standard pre-treatment, 
concentrated sputum samples presented very different 
gel strengths. The gel strengths of the original sputum 
samples were very different. We could distinguish 3 cat-
egories of sample based on the G′ values of the untreated 
samples determined at an angular frequency of 1 rad/s in 
the resting phase of the measurements: (i) highly elastic 
(G′ > 100,000  Pa), (ii) elastic (100,000  Pa > G′ > 1000  Pa) 
and (iii) viscoelastic (G′ < 1000) sputum samples. Based 
on these categories, the efficacy of the treatments was 
evaluated for all samples by category and the mixing 
ratio of the sputum and additives: 10:4 (Table 1) and 10:1 
(Table 2).
When a large volume of additive (10:4, Table  1, Box 
plots of the results are presented in Additional file  1: 
Figures S-1–4) was applied, the viscoelastic moduli (G′ 
and G″) decreased, while the loss factor (tanδ) increased, 
indicating the destruction of the highly elastic gel struc-
ture. Only the hypertonic  NaHCO3 solution caused sig-
nificant changes in all rheological parameters, whereas 
distilled water and hypertonic NaCl solution did not 
change the loss factor values.
When the results were evaluated by category, all addi-
tives significantly decreased the rheological parameters 
of the highly elastic and elastic sputum samples (with the 
exception of the loss factor). However, the most effective 
additive was bicarbonate (the lowest G′ and G″ values).
For elastic and viscoelastic samples, where the sputum 
had a more liquid state, the additives did not induce sig-
nificant changes in the rheological parameters, only in 
the case of bicarbonate or water we could find significant 
change in some parameters (G′ and loss factor).
When using lower volumes of additives (10:1, Table 2), 
we observed a tendency for decreased values in the rheo-
logical parameters (especially using  NaHCO3 or NaCl 
solutions for highly elastic sputum samples). However, 
because of the variability of the samples, the differences 
were not statistically significant at this mixing ratio 
(Table 2, Box plots of the results are presented in Addi-
tional file 1: Figures S-5–8).
Discussion
Several previous studies have investigated the rheologi-
cal properties of CF sputum samples and shown that 
they have viscoelastic behaviour, which can be stud-
ied by oscillatory rheometry (microbead rheology or 
shear rheology) [8]. Nonetheless, rheological measure-
ments of sputum samples face a number of challenges. 
Samples from spontaneous expectoration are normally 
diluted by saliva, thus pre-separation is required to 
assess the properties of the sputum itself. Sputum sam-
ples may exhibit significant variability, even from the 
same individual. There are many possible explanations 
for this, for example colonization with different bacte-
ria, differences in ASL composition, various degrees of 
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contamination by saliva [14, 15], and different intensi-
ties or frequencies of repetitive voluntary cough. Any of 
these factors can alter the solid content and the hydra-
tion level of the sputum and thus its viscoelastic prop-
erties [16]. The small sample size and heterogeneity 
within the sample can also complicate the analysis.
In the present study, we investigated some of the meth-
odological factors influencing the rheological meas-
urements. Sputum samples were separated from saliva 
by using the centrifugation technique described previ-
ously in the literature [4, 17]. After separation, the spu-
tum gel phase was gently homogenized by stirring. For 
Fig. 3 Resting phase of sputum samples after different treatments in the case of different patients
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rheological analysis, a resting measurement phase was 
introduced to investigate whether pre-homogenization, 
the mechanical effects of sample agitation and insertion 
into the rheometer, or storage temperature could affect 
the rheological parameters and their change over time. 
Our results clearly demonstrate that the introduction of 
the resting phase into the measurement protocol is rec-
ommended because sputum samples undergo significant 
changes once inserted into the rheometer, which could 
be due to the unavoidable but disruptive effects of sample 
operation. The length of this section can be optimized for 
a given instrument and preparatory operation. It should 
be long enough for stabilization of the parameters. How-
ever, efforts should be made to limit the preparation time 
as short as possible to avoid the dehydration and degra-
dation of the samples. In our experiments we established 
this time period of 30 min.
The technique used to mix the sputum with additives, 
such as mucolytics, can significantly alter the initial 
rheological properties of the sample. For example, the 
gel structure was broken down after ultrasonication 
and did not recover during the test stage. In contrast, 
Table 1 Rheological parameters of the sputum using a sputum: additive ratio of 10:4
Untreated Water bicarbonate NaCl
Mean (SD) Mean (SD) p value Mean (SD) p value Mean (SD) p value
For all samples
G′ (at 1 rad/s) 82,037 (± 84,967) 64,556 (± 64,832) 0.0161 41,073 (± 45,478) 0.0009 24,741 (± 35,553) 0.0110
G″ (at 1 rad/s) 20,926 (± 20,403) 16,557 (± 16,337) 0.0597 10,854 (± 11,264) 0.0029 6480 (± 8756) 0.0312
tanδ (at 1 rad/s) 0.2647 (± 0.0426) 0.2665 (± 0.0596) 0.6548 0.3163 (± 0.1631) 0.0049 0.3051 (± 0.0999) 0.5052
G′ (at 10 rad/s) 101,422 (± 109,431) 80,410 (± 83,619) 0.0122 49,784 (± 54,697) 0.0013 47,712 (± 45,942) 0.0223
G″ (at 10 rad/s) 23,882 (± 25,490) 18,108 (± 18,133) 0.0467 11,963 (± 12,200) 0.0051 12,135 (± 10,962) 0.0799
tanδ (at 10 rad/s) 0.2391 (± 0.0479) 0.2575 (± 0.0817) 0.7346 0.3172 (0.1754) 0.0015 0.2823 (± 0.0504) 0.4369
n = 16 n = 16 n = 14 n = 9
For highly elastic sample 
(G′ > 100 000 Pa)
G′ (at 1 rad/s) 161,725 (± 95,700) 49,150 (± 47,894) < 0.0001 28,770 (± 34,739) < 0.0001 35,445 (± 33,747) < 0.0001
G″ (at 1 rad/s) 39,393 (± 27,405) 12,338 (± 12,035) < 0.0001 6823 (± 7914) < 0.0001 8614 (± 7765) < 0.0001
tanδ (at 1 rad/s) 0.2393 (± 0.0351) 0.2580 (± 0.0727) 0.9311 0.3104 (± 0.1853) 0.1883 0.2875 (± 0.0841) 0.5394
G′ (at 10 rad/s) 204,250 (± 123,409) 60,679 (± 61,262) < 0.0001 35,913 (± 43,801) < 0.0001 46,762 (± 42,154) < 0.0001
G″ (at 10 rad/s) 46,568 (± 35,515) 13,706 (± 13,323) 0.0002 8099 (± 9650) < 0.0001 10,937 (± 9471) 0.0002
tanδ (at 10 rad/s) 0.2192 (± 0.0312) 0.2431 (± 0.0895) 0.8880 0.3259 (± 0.2016) 0.0367 0.2665 (± 0.0522) 0.5963
n = 34 n = 34 n = 28 n = 22
For elastic sample (100 
000 Pa > G′ > 1000 Pa)
G′ (at 1 rad/s) 33,999 (± 23,742) 18,133 (± 21,186) 0.0395 17,151 (± 23,067) 0.0398 27,299 (± 38,056) 0.6779
G″ (at 1 rad/s) 8435 (± 5620) 4919 (± 5606) 0.0943 4664 (± 6284) 0.0902 7122 (± 10,032) 0.8262
tanδ (at 1 rad/s) 0.2549 (± 0.0355) 0.2936 (± 0.0536) 0.1204 0.3377 (± 0.1364) 0.0003 0.2949 (0.0671) 0.1623
G′ (at 10 rad/s) 40,702 (± 28,571) 21,513 (± 25,010) 0.0486 20,935 (± 27,391) 0.0583 35,549 (± 50,749) 0.8957
G″ (at 10 rad/s) 9585 (± 6505) 5303 (± 5905) 0.0783 5298 (± 6824) 0.1046 8913 (± 12,723) 0.9811
tanδ (at 10 rad/s) 0.2421 (± 0.0379) 0.2683 (0.0630) 0.7026 0.3427 (± 0.2224) 0.0040 0.2962 (± 0.0835) 0.2315
n = 14 n = 14 n = 12 n = 6
For viscoelastic sample 
(1000 Pa > G′)
G′ (at 1 rad/s) 272.3 (± 416.7) 368.7 (± 864.8) 0.9746 168.7 (± 268.6) 0.9660 729.7 (± 1031.5) 0.3555
G″ (at 1 rad/s) 117.2 (± 200.1) 129.4 (± 320.2) 0.4434 60.7 (± 109.5) 0.9831 183.6 (± 260.8) 0.9834
tanδ (at 1 rad/s) 0.3885 (± 0.0906) 0.3550 (± 0.1660) 0.9032 0.3815 (± 0.0986) 0.9988 0.3333 (± 0.2049) 0.7357
G′ (at 10 rad/s) 198.2 (± 246.7) 415.7 (± 965.8) 0.8411 217.2 (± 349.0) 0.9999 852.7 (± 1338.6) 0.1843
G″ (at 10 rad/s) 74.2 (± 100.8) 149.9 (± 366.57) 0.8290 74.2 (± 136.1)  > 0.9999 226.9 (± 377.3) 0.4675
tanδ (at 10 rad/s) 0.3446 (± 0.1088) 0.3545 (± 0.2431) 0.9991 0.3662 (± 0.2928) 0.9907 0.3766 (± 0.1579) 0.9818
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pre-warming the samples did not appear to change the 
gel structure.
The rheological properties of sputum can be influ-
enced by a number of factors, such as solid content, the 
degree of hydration, pH, electrolyte concentrations, the 
quantity and types of mucins, extracellular materials 
(e.g. extracellular DNA and F-actin), and interactions 
between mucin chains or with other molecules [18]. 
Mucolytic agents mainly target these interactions, but 
they may also influence the pH and/or hydration state 
of the ASL.
The use of hypertonic saline (HS) solution is an inex-
pensive, safe, and effective additional therapy in CF 
patients with stable lung function [19]. The inhalation of 
HS solution can improve mucociliary clearance due to its 
hyperosmolarity, where water transport into the airways 
is driven by osmosis, resulting in a deeper periciliary fluid 
layer and enhanced mucus hydration [20, 21]. Elkins and 
co-workers reported significant benefits of hypertonic 
saline inhalation in a 48‐week parallel group study, in 
which 164 CF patients were randomised to receive either 
7% HS (300  mmol/L NaCl) or placebo (150  mmol/L 
Table 2 Rheological parameters of the sputum using a sputum: additive ratio of 10:1
Untreated Water Bicarbonate NaCl
Mean (SD) Mean (SD) p value Mean (SD) p value Mean (SD) p value
For all samples
G′ (at 1 rad/s) 67,359 (± 88,421) 67,175 (± 66,877) > 0.9999 57,423 (± 73,261) 0.9789 126,093 (± 218,382) 0.9996
G″ (at 1 rad/s) 16,900 (± 20,838) 16,808 (± 17,012) > 0.9999 14,590 (± 17,772) 0.9822 32,291 (± 55,925) > 0.9999
tanδ (at 1 rad/s) 0.2654 (± 0.0400) 0.2483 (± 0.0359) 0.7877 0.2700 (± 0.0399) 0.9936 0.3623 (± 0.2026) 0.1841
G′ (at 10 rad/s) 85,329 (± 114,754) 83,220 (± 86,399) > 0.9999 71,183 (± 87,859) 0.9697 82,689 (± 128,089) 0.9999
G″ (at 10 rad/s) 20,040 (± 26,749) 18,140 (± 18,996) 0.9932 16,429 (± 19,110) 0.9576 19,947 (± 29,187) > 0.9999
tanδ (at 10 rad/s) 0.2444 (± 0.0497) 0.2325 (± 0.0447) 0.8464 0.2565 (± 0.0465) 0.8355 0.2669 (± 0.0481) 0.5015
n = 4 n = 4 n = 4 n = 3
For highly elastic sample 
(G′ > 100 000 Pa)
G′ (at 1 rad/s) 183,109 (± 94,456) 111,662 (± 75,718) 0.3810 74,551 (± 50,395) 0.1225 45,154 (± 34,271) 0.0641
G″ (at 1 rad/s) 43,568 (± 21,332) 27,415 (± 21,453) 0.4412 18,263 (± 11,377) 0.1459 10,924 (± 7285) 0.0745
tanδ (at 1 rad/s) 0.2432 (± 0.0299) 0.2272 (± 0.0362) 0.8908 0.2502 (± 0.0315) 0.9886 0.2526 (± 0.0595) 0.9786
G′ (at 10 rad/s) 236,912 (± 122,817) 145,972 (± 103,271) 0.3999 93,302 (± 60,342) 0.1168 58,010 (± 43,427) 0.0659
G″ (at 10 rad/s) 54,340 (± 29,671) 32,120 (± 24,897) 0.3797 20,330 (± 13,121) 0.1185 13,729 (± 9456) 0.0803
tanδ (at 10 rad/s) 0.2283 (± 0.0243) 0.2075 (± 0.0246) 0.6740 0.2178 (± 0.0061) 0.9320 0.2420 (± 0.0578) 0.8889
n = 7 n = 7 n = 7 n = 6
For elastic sample (100 
000 Pa > G′ > 1000 Pa)
G′ (at 1 rad/s) 33,999 (± 23,742) 18,133 (± 21,186) 0.5433 17,151 (± 23,067) 0.9883 27,299 (± 38,056) 0.7230
G″ (at 1 rad/s) 8435 (± 5620) 4919 (± 5606) 0.6247 4664 (± 6284) 0.9900 7122 (± 10,032) 0.5802
tanδ (at 1 rad/s) 0.2549 (± 0.0355) 0.2936 (± 0.0535) > 0.9999 0.3427 (± 0.2224) 0.3416 0.2949 (± 0.0671) 0.7706
G′ (at 10 rad/s) 40,702 (± 28,571) 21,513 (± 25,010) 0.5474 20,935 (± 27,391) 0.9925 35,549 (± 50,749) 0.8276
G″ (at 10 rad/s) 9585 (± 6505) 5303 (± 5905) 0.6678 5298 (± 6824) 0.9989 8913 (± 12,723) 0.7473
tanδ (at 10 rad/s) 0.2421 (± 0.0379) 0.2683 (± 0.0631) 0.7958 0.3427 (± 0.2224) 0.3426 0.2962 (± 0.0835) 0.2537
n = 5 n = 5 n = 4 n = 4
For viscoelastic sample 
(1000 Pa > G′)
G′ (at 1 rad/s) 1453.5 (± 2831.3) 1104.9 (± 1875.1) 0.9921 1306.7 (± 1502.5) 0.9994 10.3 (± 13.3) 0.7975
G″ (at 1 rad/s) 438.8 (± 854.2) 360.2 (± 614.7) 0.9968 393.6 (± 456.2) 0.9994 2.6 (± 2.9) 0.8069
tanδ (at 1 rad/s) 0.2880 (± 0.0269) 0.2623 (± 0.0582) 0.9696 0.2783 (± 0.0368) 0.5187 0.4155 (± 0.2553) 0.9982
G′ (at 10 rad/s) 2309.5 (± 4540.5) 682.8 (± 1132.2) 0.8451 2011.5 (± 2365.9) 0.9986 528.1 (± 709.9) 0.8572
G″ (at 10 rad/s) 698.7 (± 1374.1) 238.0 (± 400.1) 0.8670 557.7 (± 675.9) 0.9948 166.2 (± 226.0) 0.8607
tanδ (at 10 rad/s) 0.2923 (± 0.0142) 0.2743 (± 0.0677) 0.9020 0.2797 (± 0.0222) 0.9614 0.2790 (± 0.0523) 0.9686
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NaCl) [21]. It was demonstrated that  FEV1 was approxi-
mately 3% higher in the HS than in the placebo group. 
The effects of other osmotic agents, mannitol [22] and 
xylitol [23, 24], have also been studied in CF patients.
The inhalation of bicarbonate-containing solutions 
could be another useful adjuvant therapy in CF.  NaHCO3 
is an effective, safe and well-tolerated therapeutic agent 
in CF and possibly in other chronically infected lung dis-
eases [7, 25, 26]. Gomez et al. have recently demonstrated 
that the inhalation of hypertonic  NaHCO3 increased the 
pH of the ASL and decreased the gel strength of the spu-
tum, which could be explained by greater expansion of 
mucins and DNA. This weakening effect of bicarbonate 
on gel strength has also been reported by Stigliani et al. 
[4] who showed that elastic and viscous moduli, as well as 
complex viscosity, were reduced after in vitro treatment. 
This group has also investigated the dissolution and per-
meation properties of ketoprofen lysinate (Klys) in CF 
sputum. Interestingly, CF sputum treated with  NaHCO3 
exhibited more rapid Klys dissolution and permeation 
than sputum without added bicarbonate [4].
In our study, the effects of NaCl and  NaHCO3 solutions 
(300  mmol/L) were investigated on CF sputum samples 
in  vitro. As a reference treatment, water was added to 
some sputum samples, which can be regarded as an indi-
cator of the hydrating effect of the additive solution with-
out the salt or bicarbonate. The overall aim of the present 
work was to develop an in  vitro method to predict the 
efficacy of topically applied mucolytics. This could help in 
selecting the most appropriate inhalation formulation for 
the disease status of each CF patient. However, it must be 
kept in mind that the method presented here is not suit-
able for assessing the beneficial in vivo osmotic effects of 
hypertonic solutions.
Storage and loss modulus as well as the loss factor 
can be used to compare the efficacy of different in vitro 
treatments. The gel structure and its viscoelastic char-
acteristics can be well characterized by measuring these 
rheological parameters. Mucus clearance is known to be 
influenced by viscoelasticity [5]. Two main mucus clear-
ance processes can be distinguished: (i) mucociliary 
clearance (MCC) and (ii) cough clearance (CC). The effi-
cacy of these clearance processes depends upon the rheo-
logical properties of sputum. In previous studies, MCC 
was simulated by using low frequency deformations 
(1 rad/s), while CC was mimicked by applying 100 rad/s. 
In micro-rheology, these frequencies correspond to 
the beating frequency of epithelial cilia and coughing, 
respectively [5, 27]. In shear rheology, it has been sug-
gested that higher frequencies should be avoided because 
the inertia of the instrument strongly affects the torque 
response of the soft CF sputum. Since it has been recom-
mended to limit frequencies to no higher than 10  rad/s 
[14, 28], we compared the rheological parameters (G′, G″ 
and tanδ) of the untreated and treated sputum at 1 and 
10 rad/s.
The sputum samples showed great variability based 
on the elastic modulus at 1  rad/s of the untreated sam-
ples. The range of these elastic moduli correspond to 
values described in a previous study [4] in which the 
same sputum preparation method was applied. Impor-
tantly, we detected 3 distinct categories: (i) highly elastic 
(G′ > 100,000  Pa), (ii) elastic (100,000  Pa > G′ > 1000  Pa), 
and (iii) viscoelastic (G′ < 1000) sputum samples. Visu-
ally the highly elastic samples were very compact and 
behaved as a solid material. Elastic samples showed 
remarkable elasticity, but they were deformable, while 
viscoelastic samples presented liquid characteristics. The 
changes in the rheological parameters, with time and 
additive pre-treatment, were therefore assessed in each 
category separately.
In this study, we did not assess the clinical status of the 
patients, thus the conclusions were drawn on the basis of 
the rheological properties of the sputum samples alone. 
They were treated either at 10:4 (n = 61) or 10:1 (n = 15) 
sputum/additive solution ratios. We used a ratio of 10:1 
(sputum/additive) based on methods published by Stigli-
ani et al. [4]. In addition, we have chosen a ratio of 10:4 
which may mimic the luminal environment following 
application of the hypertonic saline and water secretion.
When using the larger volume of additive (10:4), the gel 
strength of the sputum decreased because the viscoelas-
tic moduli decreased and the loss factor increased at each 
frequency. The pronounced variability of the samples is 
reflected in the large standard deviation values, which are 
even more noticeable in the treated samples. Importantly, 
we found that the added solutions significantly reduced 
the gel strength of the sputum considering all investi-
gated samples, but the most pronounced changes (lowest 
p values) were observed for  NaHCO3 (p < 0.001). Samples 
with high elasticity (G′ > 100,000 Pa) exhibited the great-
est changes in the parameters, suggesting that dilution 
of the gel structure may result in the greatest structural 
breakdown in samples of this type. It is remarkable that 
even more significant effects were detected when the 
samples were treated by  NaHCO3.
For less elastic samples, a weakening of the gel struc-
ture was also observed when they were treated with 
distilled water or  NaHCO3, but not with NaCl solution, 
where there were no significant changes in the parame-
ters. For viscoelastic samples with a low elastic content, 
the additives did not cause significant changes in the 
parameters.
For all samples at 10:4 ratio, the effect of additives 
significantly reduces the rheological parameters of the 
sputum, but when the changes within the categories are 
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analysed, it is clear that the reducing effect is mostly lim-
ited to samples with significant elasticity (highly elastic 
and elastic samples), at low elasticity no significant effect 
can be observed.
When a lower additive volume (10:1 ratio) was used, 
the mean values of the rheological parameters usually 
decreased, especially in the case of the highly elastic spu-
tum samples following treatment with either  NaHCO3 or 
NaCl solutions. A decrease in modulus was also observed 
in this additive ratio. The effects of NaCl were the most 
remarkable (but not significant) in the most elastic sam-
ples, while the efficacy of  NaHCO3 was highest in the 
middle category (lower mean values observed in the case 
of the treated samples, in Table 2). The beneficial effects 
of NaCl could also be observed in the sputum samples 
with the lowest elastic content (G′ < 1000 Pa). Consider-
ing all samples treated with 10:1 sputum to additive ratio, 
the bicarbonate treated samples showed the lowest mean 
rheological parameters (and thus the more effective 
treatment), but within the categories this tendency is not 
prevailed, the effect of additives is different in the case of 
samples with different rheological profiles. However, it 
should be noted that no significance was detected in this 
sputum/additive ratio.
When comparing the alternative sputum/additive 
ratios used here, it is evident that larger amounts of 
added water alone can significantly reduce the gel char-
acter of the sputum samples. Based on the rheological 
properties of the initial sputum samples, it may be appro-
priate to categorize the treatment efficacy by each addi-
tive. The difference between the categories suggests that 
it is advisable to evaluate each sample individually. These 
efficacy measurements in vitro may be suitable for such 
an assessment.
In accordance with previously published observations, 
the standard deviations of the mean values were also high 
in the present work, which rendered the statistical analy-
sis of the data difficult. However, the introduction of the 
resting phase, or the equilibration of the samples imme-
diately before measurements may reduce the inaccuracy 
of the data.
Conclusion
In this study we have assessed and compared in  vitro 
the effects of hypertonic mucolytics that are used 
locally as inhaled aerosols for adjuvant therapy in CF. 
Our data suggest that the pre-treatment and handling 
of sputum samples can exert significant effects on their 
rheological properties. Thus, it is important to inves-
tigate the adverse effects of sample treatment in all 
applied rheological methods. In assessing the effects 
of hypertonic NaCl and  NaHCO3 solutions on CF spu-
tum samples, we observed that these mucolytic agents 
exhibit different effects on sputum samples according 
to their initial viscoelastic characteristics. Our results 
suggest that it is advisable to evaluate each sample indi-
vidually, and our measurements for the analysis of the 
efficacy of the additives in  vitro may be suitable for 
such an assessment.
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